April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more
Immune medicines company Repertoire Immune Medicines Inc. raised $189 million in a series B financing from founding investor Flagship Pioneering and other investors including Softbank Vision Fund 2i, the Public Sector Pension Investment Board (PSP Investments), the Alaska Permanent Fund and Invus. Repertoire, which debuted in March 2020 after the December 2019 merger of two other Flagship companies, has raised more than $350 million. Led by CEO John Cox and Chairman and Flagship Managing Partner Douglas Cole, the company aims to identify which TCRs and antigens matter in disease and apply those insights to biomarkers and therapies, starting with cytokine-loaded T cell candidates for cancer.
Samsara, CAM lead Arcellx’s $115M series C
Arcellx Inc. raised $115 million in a series C round co-led by Samsara BioCapital and CAM Capital to develop its adaptive and controllable cell therapies. New investors Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Citadel’s Surveyor Capital, Suvretta, and Terra Magnum Capital Partners, joined existing investors NEA, Novo Holdings, SR One, Takeda Ventures, LG Tech, and Clough Capital in the financing. The company’s CART-ddBCMA, a BCMA-specific CAR-modified T cell therapy in Phase I testing, is expected to enter a pivotal trial in 2022...